Calidi Biotherapeutics, Inc. Announces Pricing of $6.1 Million Public Offering

Rhea-AI Summary

Calidi Biotherapeutics, Inc. (CLDI) announces the pricing of a $6.1 million public offering, consisting of common stock and warrants, to fund its immunotherapy development. The offering includes 15,197,500 shares at $0.40 per share, with various warrant types. The gross proceeds are approximately $6.1 million before expenses.

SAN DIEGO--(BUSINESS WIRE)-- Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the pricing of its “reasonable best efforts” public offering of 15,197,500 shares of common stock (or pre-funded warrants in lieu thereof) and accompanying Series A Common Warrants, Series B Unit Warrants, with each unit consisting of one share of common stock and a Series B-1 Common Warrant and Series C Unit Warrants, with each unit consisting of one share of common stock and a Series C-1 Common Warrant (or common stock equivalents in lieu thereof) at an effective combined price of $0.40 per share and common warrants for aggregate gross proceeds of approximately $6.1 million, before deducting placement agent fees and other offering expenses. The common warrants will have an exercise price of $0.60 per share, and the Series A Common Warrants, Series B Unit Warrant and Series C Unit Warrant will be exercisable immediately. The common warrants will expire in five years (with respect to the Series A Common Warrant, the Series B-1, Warrant and the Series C-1 Common Warrant), twelve months (with respect to the Series B common warrants) and four months (with respect to the Series C common warrants) from the issuance date.

The closing of the offering is expected to occur on or about April 18, 2024, subject to the satisfaction of customary closing conditions. The Company currently intends to use a portion of the net proceeds of this offering for working capital and general corporate purposes, and pre-clinical and clinical trials subject to the actual amount of proceeds received.

Ladenburg Thalmann & Co. Inc. is acting as sole placement agent in connection with the offering.

The securities described above are being offered pursuant to a registration statement on Form S-1 (File No. 333-276741) previously filed with the Securities and Exchange Commission (SEC) which became effective on April 15, 2024. The offering is being made only by means of a prospectus forming part of the effective registration statement. Copies of the preliminary prospectus and, when available, copies of the final prospectus, relating to the offering may be obtained on the SEC’s website located at http://www.sec.gov. Electronic copies of the final prospectus relating to the offering may be obtained, when available, from Ladenburg Thalmann & Co. Inc., 640 Fifth Avenue, 4^th Floor, New York, New York 10019, or by telephone at (212) 409-2000, or by email at prospectus@ladenburg.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Calidi Biotherapeutics:

Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer. Calidi’s novel stem cell-based platforms are utilizing potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi’s clinical stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. This dual approach can potentially treat, or even prevent, metastatic disease. Calidi Biotherapeutics is headquartered in San Diego, California. For more information, please visit www.calidibio.com

Forward-Looking Statements

This press release may contain forward-looking statements for purposes of the “safe harbor” provisions under the United States Private Securities Litigation Reform Act of 1995. Terms such as “anticipates,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predicts,” “project,” “should,” “towards,” “would” as well as similar terms, are forward-looking in nature, but the absence of these words does not mean that a statement is not forward-looking. These forward looking statements include, but are not limited to, statements concerning use of proceeds from the offering, that the closing of offering will occur or will occur on the anticipated closing date, upcoming key milestones, planned clinical trials, and statements relating to the safety and efficacy of Calidi’s therapeutic candidates in development. Any forward-looking statements contained in this discussion are based on Calidi’s current expectations and beliefs concerning future developments and their potential effects and are subject to multiple risks and uncertainties that could cause actual results to differ materially and adversely from those set forth or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that Calidi is not able to raise sufficient capital to support its current and anticipated clinical trials, the risk that early results of clinical trials do not necessarily predict final results and that one or more of the clinical outcomes may materially change following more comprehensive review of the data, and as more patient data becomes available, the risk that Calidi may not receive FDA approval for some or all of its therapeutic candidates. Other risks and uncertainties are set forth in the section entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the Company’s Form 10-K filed on March 15, 2024, and Amendment No. 5 to Form S-1 filed on April 15, 2024.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240415682920/en/

For Investors:

Stephen Jasper

Gilmartin Group

stephen@gilmartinir.com

For Media:

Stephen Thesing

ir@calidibio.com

Source: Calidi Biotherapeutics, Inc.

FAQ

What did Calidi Biotherapeutics announce regarding a public offering?

Calidi Biotherapeutics, Inc. (CLDI) announced the pricing of a $6.1 million public offering.

How many shares were included in the public offering by Calidi Biotherapeutics?

Calidi Biotherapeutics included 15,197,500 shares in the public offering.

At what price per share was the public offering by Calidi Biotherapeutics priced?

The public offering by Calidi Biotherapeutics was priced at $0.40 per share.

What is the total gross proceeds from the public offering by Calidi Biotherapeutics?

The total gross proceeds from the public offering by Calidi Biotherapeutics are approximately $6.1 million before expenses.

What are the exercise prices and expiration dates of the common warrants in the public offering by Calidi Biotherapeutics?

The common warrants in the public offering by Calidi Biotherapeutics have an exercise price of $0.60 per share and expire in five years for Series A, Series B-1, and Series C-1 warrants, twelve months for Series B warrants, and four months for Series C warrants.